

# International Conference **OncoNephrology**

## An Emerging Field In Medicine

*Organized by*

Prof. Giovambattista Capasso

Prof. Fortunato Ciardiello



**biogem**

Promoted by



FONDAZIONE  
INTERNAZIONALE  
MENARINI

FINAL PROGRAMME

Naples (Italy), December 7-9, 2017

**OncoNephrology** is an emerging field in medicine. Cancer patients may suffer of particular renal diseases that necessitate a joined and specialized approach. Furthermore, cancer therapy often causes both acute and chronic kidney injuries and the introduction of many targeted therapies have made more frequent the association between kidney disease and cancer. Besides, the evident improvements in cancer therapy have led to a longer survival of cancer patients affected by reduced kidney function.

Based on these observations, it is mandatory that nephrologists should become more expert of cancer biology and therapy in order to deliver the best nephrology care possible and to be fully integrated in the multidisciplinary team approach to most cancer patients.

In this meeting we will address the key issues at this challenging clinical interface including many unresolved basic science questions such as the high frequency of tumours in kidney transplanted patients. To this end, we have gathered highly qualified faculty members from all over the world and we have also invited young nephrologists and oncologists to present their original observations that will be highlighted in two large poster sessions.

Finally we would like to thank Menarini International Foundation for the generous support that has made possible the realization of this large international conference.

# Presidents of the Conference

Giovambattista Capasso - *Naples, Italy*

Fortunato Ciardiello - *Naples, Italy*

## Faculty

Todd R. Alexander - *Alberta, Canada*

Lucia Altucci - *Naples, Italy*

Hatem Amer - *Rochester, USA*

Akitaka Ariga - *Berne, Switzerland*

Ariela Benigni - *Bergamo, Italy*

Joseph V. Bonventre - *Boston, USA*

Giovanni Camussi - *Turin, Italy*

Anna Capasso - *Denver, USA*

Umberto Capitano - *Milan, Italy*

Michele Caraglia - *Naples, Italy*

Andrés Cervantes - *Valencia, Spain*

Franco Citterio - *Rome, Italy*

Laura Cosmai - *Milan, Italy*

Farhad R. Danesh - *Houston, USA*

Bruno Daniele - *Benevento, Italy*

Antonietta D'Errico - *Bologna, Italy*

Gilberto De Castro - *Sao Paulo, Brasil*

Marco de Sio - *Naples, Italy*

Ferdinando De Vita - *Naples, Italy*

Xiaoqiang Ding - *Shanghai, China*

Vincenzo Di Marzo - *Laval, Canada*

Antonio Ereditato - *Berne, Switzerland*

Geppino Falco - *Naples, Italy*

Denis Fouque - *Lyon, France*

Renato Franco - *Naples, Italy*

Maurizio Gallieni - *Milan, Italy*

Antonio Gambardella - *Naples, Italy*

Giovanni Gambaro - *Rome, Italy*

Loreto Gesualdo - *Bari, Italy*

Giuseppe Grandaliano - *Foggia, Italy*

Diego Ingrosso - *Naples, Italy*

Calvin Kuo - *Stanford, USA*

Edgar A. Jaimes - *New York, USA*

Amit Lahoti - *Houston, USA*

Gaetano La Manna - *Bologna, Italy*

Vincent Launay-Vacher - *Paris, France*

Francesca Mallamaci - *Reggio Calabria, Italy*

Jolanta Malysko - *Bialystok, Poland*

Paolo Manunta - *Milan, Italy*

Gennaro Marino - *Naples, Italy*

Erica Martinelli - *Naples, Italy*

Giuseppe Matarese - *Naples, Italy*

Takeshi Matsubara - *Kyoto, Japan*

Piergiorgio Messa - *Milan, Italy*

Carlo Messina - *Milan, Italy*

Antimo Migliaccio - *Naples, Italy*

Floriana Morgillo - *Naples, Italy*

Alessandro Nanni Costa - *Rome, Italy*

Michele Orditura - *Naples, Italy*

Antonello Pani - *Cagliari, Italy*

Paolo Vincenzo Pedone - *Naples, Italy*

Mark Anthony Perazella - *New Haven, USA*

Alessandra Perna - *Naples, Italy*

Claudio Pisano - *Ariano Irpino, Italy*

Todd Pitts - *Denver, USA*

Camillo Porta - *Pavia, Italy*

Giuseppe Procopio - *Milan, Italy*

Qi Qian - *Rochester, USA*

Giuseppe Remuzzi - *Bergamo, Italy*

Pierre Roncò - *Paris, France*

Mitchell H. Rosner - *Charlottesville, USA*

Domenico Russo - *Naples, Italy*

Lilian L. Siu - *Toronto, Canada*

Walter Stadler - *Chicago, USA*

Francesco Trepiccione - *Naples, Italy*


Teresa Troiani - *Naples, Italy*

Alessandro Weisz - *Salerno, Italy*

Andrzej Więcek - *Katowice, Poland*

Ortensio Zecchino - *Ariano Irpino, Italy*

Carmine Zoccali - *Reggio Calabria, Italy*





## Thursday, December 7<sup>th</sup>

- 8.00 a.m.** Registration
- 9.00 a.m.** Opening Ceremony

**9.45 a.m.** **OPENING LECTURE**

Chairperson: Francesca Mallamaci (*Reggio Calabria, Italy*)

### Why a conference on onco-nephrology?

Mark Anthony Perazella (*New Haven, USA*)

- 10.15 a.m.** Discussion
- 10.30 a.m.** *Coffee Break*

## **SESSION I**

### **ADVANCED TECHNOLOGIES II**

Chairpersons: Antonio Ereditato (*Berne, Switzerland*), Giuseppe Matarese (*Naples, Italy*)

- 11.00 a.m.** Role of extracellular vesicles in tumor biology  
Giovanni Camussi (*Turin, Italy*)
- 11.20 a.m.** Humanized mice as Models for Human Diseases  
Anna Capasso (*Denver, USA*)
- 11.40 a.m.** Cellular metabolic pathways and tumor growth  
Todd Pitts (*Denver, USA*)
- 12.00 p.m.** Discussion

# Thursday, December 7<sup>th</sup>

## 12.15 p.m. **KEY NOTE LECTURE 1**

Chairperson: Piergiorgio Messa (Milan, Italy)

How to measure kidney function in cancer patients:  
the need for common grounds

Carmine Zoccali (*Reggio Calabria, Italy*)

1.00 p.m. Lunch

## POSTER DISCUSSION

Chairpersons: Gennaro Marino (Naples, Italy), Alessandra Perna (Naples, Italy),  
Antonio Gambardella (Naples, Italy), Teresa Troiani (Naples, Italy)

## SESSION I

### ADVANCED TECHNOLOGIES II


Chairpersons: Paolo Vincenzo Pedone (Naples, Italy), Geppino Falco (Naples, Italy)

2.30 p.m. pH reversal in cancer and pH measurement in vivo  
Qi Qian (*Rochester, USA*)

2.50 p.m. Intravital microscopy and real-time data processing  
Akitaka Ariga (*Berne, Switzerland*)

3.10 p.m. Epigenone alterations in leukemias  
Lucia Altucci (*Naples, Italy*)

3.30 p.m. Discussion







Thursday, December 7<sup>th</sup>

## SESSION II

### CANCER IN SOLID ORGAN TRANSPLANT PATIENTS

*Chairpersons:* Alessandro Nanni Costa (Rome, Italy), Renato Franco (Naples, Italy)

**3.45 p.m.** My kidney transplant candidate had cancer. Should we proceed?

*Giuseppe Grandaliano (Foggia, Italy)*

**4.05 p.m.** My kidney transplant recipient has cancer. Now what?

*Andrzej Więcek (Katowice, Poland)*

**4.25 p.m.** Could a patient with cancer be an organ donor?

*Antonietta D'Errico (Bologna, Italy)*

**4.45 p.m.** Screening for cancer in kidney transplant recipient

*Hatem Amer (Rochester, USA)*

**5.05 p.m.** Discussion

**5.25 p.m.** *Coffee Break*

**5.55 p.m.** **KEY NOTE LECTURE 2**

*Chairperson:* Franco Citterio (Rome, Italy)

The state of art of cancer research in Europe

*Fortunato Ciardiello (Naples, Italy)*

**6.25 p.m.** Discussion


Friday, December 8<sup>th</sup>

### SESSION III

## KIDNEY DISEASES AND ANTICANCER THERAPY

Chairpersons: Jolanta Malyszko (*Bialystok, Poland*), Michele Caraglia (*Naples, Italy*)

- 8.30 a.m.** Epidemiology of cancer in patients with chronic kidney disease  
Edgar A. Jaimes (*New York, USA*)
- 8.50 a.m.** Dosage adjustment and timing of chemotherapy in chronic kidney disease  
Vincent Launay-Vacher (*Paris, France*)
- 9.10 a.m.** Nephrotoxicity from cytotoxic chemotherapy  
Farhad R. Danesh (*Houston, USA*)
- 9.30 a.m.** Management of anticancer therapy in patients under chronic dialysis  
Takeshi Matsubara (*Kyoto, Japan*)
- 9.50 a.m.** Discussion
- 10.10 a.m.** *Coffee Break*
- 10.50 a.m.** **KEY NOTE LECTURE 3**  
Chairperson: Diego Ingrosso (*Naples, Italy*)  
Organoid models of cancer  
Calvin Kuo (*Stanford, USA*)
- 11.10 a.m.** Discussion



Friday, December 8<sup>th</sup>

## **SESSION IV**

### CLINICAL EFFICACY OF NOVEL MOLECULAR THERAPIES

*Chairpersons:* Ferdinando De Vita (Naples, Italy), Alessandro Weisz (Salerno, Italy)

- 11.20 a.m.** Agents targeting EGFR  
Gilberto De Castro (Sao Paulo, Brasil)
- 11.40 a.m.** Agents targeting VEGF  
Lilian L. Siu (Toronto, Canada)
- 12.00 p.m.** Agents targeting PD-1 and PD-L1  
Walter Stadler (Chicago, USA)
- 12.20 p.m.** Discussion

**12.35 p.m.** **KEY NOTE LECTURE 4**

*Chairperson:* Ortensio Zecchino (Ariano Irpino, Italy)

How we wish to die and how they force us to die  
Giuseppe Remuzzi (Bergamo, Italy)

- 1.05 p.m.** Discussion
- 1.15 p.m.** Lunch

## **POSTER DISCUSSION**

*Chairpersons:* Claudio Pisano (Ariano Irpino, Italy), Domenico Russo (Naples, Italy),  
Floriana Morgillo (Naples, Italy), Erica Martinelli (Naples, Italy)




Friday, December 8<sup>th</sup>

## SESSION V

### RENAL CANCER UPDATE

Chairpersons: **Marco de Sio** (*Naples, Italy*), **Antimo Migliaccio** (*Naples, Italy*)

- 2.45 p.m.** Adjuvant therapy for renal cancer: disappointments and hopes  
**Andrés Cervantes** (*Valencia, Spain*)
- 3.05 p.m.** Which recommendations for first-line treatment in metastatic renal cell carcinoma?  
**Camillo Porta** (*Pavia, Italy*)
- 3.25 p.m.** Beyond tyrosine kinase inhibitor therapy: the value of immunotherapy for renal cell carcinoma  
**Giuseppe Procopio** (*Milan, Italy*)
- 3.45 p.m.** The role of nephron sparing surgery  
**Umberto Capitanio** (*Milan, Italy*)
- 4.05 p.m.** Discussion
- 4.25 p.m.** *Coffee Break*





Friday, December 8<sup>th</sup>

## **SESSION VI**

### **CANCER AND THE KIDNEY**

*Chairpersons:* **Antonello Pani** (*Cagliari, Italy*), **Michele Orditura** (*Naples, Italy*)

- 4.55 p.m.** Kidney disease associated with lymphomas and leukemia  
**Carlo Messina** (*Milan, Italy*)
- 5.15 p.m.** Glomerular diseases associated with cancer  
**Loreto Gesualdo** (*Bari, Italy*)
- 5.35 p.m.** Multiple myeloma and the kidney  
**Amit Lahoti** (*Houston, USA*)
- 5.55 p.m.** Ethics of Renal Replacement Therapy in patients with advanced malignancies  
**Laura Cosmai** (*Milan, Italy*)
- 6.15 p.m.** Discussion



# Saturday, December 9<sup>th</sup>

## 8.30 a.m. **KEY NOTE LECTURE 5**

Chairperson: Pierre Roncò (*Paris, France*)

The Changing Landscape of Phase I Trials in Oncology  
Lilian L. Siu (*Toronto, Canada*)

9.00 a.m. Discussion

## **SESSION VII**

### ACUTE KIDNEY INJURY (AKI) IN CANCER

Chairpersons: Giovanni Gambaro (*Rome, Italy*), Gaetano La Manna (*Bologna, Italy*)

9.10 a.m. Molecular mechanisms of AKI: the role of Sirtuin-3  
Ariela Benigni (*Bergamo, Italy*)

9.30 a.m. AKI burden in Cancer  
Joseph V. Bonventre (*Boston, USA*)

9.50 a.m. Renal Replacement Therapy in cancer patients with AKI  
Maurizio Gallieni (*Milan, Italy*)

10.10 a.m. AKI from the use of contrast medium in cancer patients  
Xiaoqiang Ding (*Shanghai, China*)

10.30 a.m. Discussion


10.50 a.m. *Coffee Break*

## 11.10 a.m. **KEY NOTE LECTURE 6**

Chairperson: Denis Fouque (*Lyon, France*)

Endocannabinoids, Phytocannabinoids and Cancer  
Vincenzo Di Marzo (*Laval, Canada*)

11.40 a.m. Discussion



Saturday, December 9<sup>th</sup>


## SESSION VIII

### ELECTROLYTE ABNORMALITIES ASSOCIATED WITH CANCER

*Chairpersons:* **Paolo Manunta** (*Milan, Italy*), **Bruno Daniele** (*Benevento, Italy*)

- 11.50 a.m.** Hyper- and hypo-calcemia in cancer patients  
**Mitchell H. Rosner** (*Charlottesville, USA*)
- 12.10 p.m.** Hyponatremia in cancer patients  
**Francesco Trepiccione** (*Naples, Italy*)
- 12.30 p.m.** Magnesium in cancer patients  
**Todd R. Alexander** (*Alberta, Canada*)
- 12.50 p.m.** Potassium in cancer patients  
**Giovambattista Capasso** (*Naples, Italy*)
- 1.10 p.m.** Discussion
- 1.30 p.m.** Lunch
- 2.30 p.m.** CME Questionnaire
- 3.30 p.m.** Closing Remarks  
**Giovambattista Capasso** (*Naples, Italy*), **Fortunato Ciardiello** (*Naples, Italy*)

Poster Session





# December 07<sup>th</sup>, 2017

1.30 pm - 3.00 pm

Discussant:

**Gennaro Marino, Alessandra Perna,  
Antonio Gambardella, Teresa Troiani**

- 1. Renal Cell Carcinoma in Donor Candidates: 16 years of Experience in Emilia-Romagna Region, Italy**  
F. Ambrosi <sup>1</sup>, F. Vasuri <sup>1</sup>, D. Malvi <sup>1</sup>, B. Fabbri <sup>1</sup>, M. Ravaioli <sup>2</sup>, C. De Cillia <sup>3</sup>, M. Fiorentino <sup>1</sup>, A. D'errico <sup>1</sup>  
<sup>(1)</sup> "F. Addari" Institute of Oncology and Transplant Pathology, Sant'Orsola-Malpighi Hospital, University of Bologna, Bologna, <sup>(2)</sup> Department of Surgery and Transplantation, Sant'Orsola-Malpighi Hospital, University of Bologna, Bologna, <sup>(3)</sup> Department of Surgery and Transplantation, Emilia-Romagna Transplant Reference Centre, Sant'Orsola-Malpighi Hospital, University of Bologna, Bologna
- 2. Incidental neoplasm after bilateral nephrectomy in polycystic kidney disease end stage renal population. A single centre experience.**  
M.I. Bellini <sup>1</sup>, P. Hill <sup>1</sup>, F. Dor <sup>1</sup>, J. Campbell <sup>1</sup>, V. Papalois <sup>1</sup>  
<sup>(1)</sup> Imperial College London
- 3. A strange case of renal arteries stenosis -**  
D. Bertoni <sup>1</sup>, V. Vizzardi <sup>1</sup>, G. Jeannin <sup>1</sup>, G. Cancarini <sup>1</sup>  
<sup>(1)</sup> ASST Spedali Civili and University of Brescia
- 4. HFR-SUPRA efficacy of treating Mieloma Kidney. Case series.**  
G. Daidola <sup>1</sup>, C. Guarena <sup>2</sup>, M. Brustia <sup>3</sup>, G. Leonardi <sup>2</sup>, F.N. Vigotti <sup>1</sup>, A. Marciello <sup>1</sup>, S. Bianco <sup>2</sup>, D. Chiarinotti <sup>3</sup>, M. Saltarelli <sup>1</sup>, L. Biancone <sup>2</sup>  
<sup>(1)</sup> S.C. Nefrologia e Dialisi ASL TO3 Rivoli e Pinerolo, <sup>(2)</sup> S.C. Nefrologia, Dialisi e Trapianto U. AOU Città della Salute e della Scienza di Torino, <sup>(3)</sup> S.S.D. Nefrologia e Dialisi, AOU Maggiore della Carità, Novara
- 5. Monoclonal gammopathy of renal significance and solid organ transplantation: two seemingly unconnected conditions?**  
B. Bonino <sup>1</sup>, N. Conti <sup>2</sup>, F. Cappadona <sup>2</sup>, R. Russo <sup>2</sup>, G. Garibotto <sup>2</sup>  
<sup>(1)</sup> policlinico san martino, <sup>(2)</sup> policlinico san martino genova
- 6. Effect of the TRC105 Monoclonal Antibody (mAb) on Renal Tumor endothelial cells**  
A. Brossa <sup>1</sup>, L. Buono <sup>1</sup>, B. Bussolati <sup>1</sup>  
<sup>(1)</sup> MOLECULAR BIOTECHNOLOGY CENTER (MBC) Università degli studi di Torino
- 7. Pharmacokinetics of Vemurafenib in a patient with metastatic melanoma and renal failure on hemodialysis. A case report**  
E. Caramella <sup>1</sup>, P. Esposito <sup>1</sup>, M. Brogna <sup>2</sup>, A.N. Bartoli <sup>2</sup>, F. Valentino <sup>3</sup>, M. Montagna <sup>2</sup>, P. Pedrazzoli <sup>3</sup>, C. Libetta <sup>1</sup>, T. Rampino <sup>1</sup>  
<sup>(1)</sup> Unit of Nephrology, Dialysis and Transplantation, Foundation IRCCS Policlinico San Matteo, Pavia, Italy, <sup>(2)</sup> Unit of Clinical and Experimental Pharmacokinetics, Foundation IRCCS Policlinico San Matteo, Pavia, Italy, <sup>(3)</sup> Unit of Oncology, Foundation IRCCS Policlinico San Matteo, Pavia, Italy
- 8. Case Report: Acute interstitial nephritis secondary to the use of Immune-Check-Point-Inhibitor (ICI) in a patient suffering from metastatic melanoma, in the absence of AKI's developmental risk factors. Review of literature**  
E. Cuka <sup>1</sup>, M. Simonini <sup>1</sup>, P. Manunta <sup>1</sup>, C. Lanzani <sup>1</sup>  
<sup>(1)</sup> University Vita Salute San Raffaele, Milan - IRCCS San Raffaele Scientific Institute, Milan
- 9. Kidney transplantation from a living donor with an undiagnosed malignancy at the time of donation: transmission of the disease and outcome.**  
C. Cianchi <sup>1</sup>, D. Giannese <sup>1</sup>, D. Moriconi <sup>1</sup>, M.F. Egidi <sup>1</sup>  
<sup>(1)</sup> University of Pisa, Department of Nephrology, Dialysis and Transplantation
- 10. Case report: Anemia and thrombocytosis as a presentation of renal oncocytoma and a review of paraneoplastic syndromes related to renal oncocytoma**  
E. Cuka <sup>1</sup>, M. Simonini <sup>1</sup>, P. Manunta <sup>1</sup>, C. Lanzani <sup>1</sup>  
<sup>(1)</sup> University Vita Salute San Raffaele, Milan - IRCCS San Raffaele Scientific Institute, Milan
- 11. Ifosfamide and renal injury: a casa report**  
M. De Fabritiis <sup>1</sup>, C. Americo <sup>1</sup>, M.L. Angelini <sup>1</sup>, S. Cristino <sup>1</sup>, M.F. Liffrieri <sup>1</sup>, L. Zambianchi <sup>1</sup>, G. Mosconi <sup>1</sup>  
<sup>(1)</sup> Nephrology and Dialysis Unit, "Morgagni-Pierantoni" Hospital, Forlì - AUSL della Romagna
- 12. Diabetes insipidus as the unique manifestation of breast metastatic carcinoma**  
M.V. Domenech <sup>1</sup>, P. Esposito <sup>1</sup>, N. Serpieri <sup>1</sup>, L. Estienne <sup>1</sup>, C. Libetta <sup>1</sup>, T. Rampino <sup>1</sup>  
<sup>(1)</sup> Department of Nephrology, Dialysis and Transplantation, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia
- 13. Renal injury (RI) associated with novel oncological therapies.**  
C. Fofi <sup>1</sup>, A.M. Aschelter <sup>2</sup>, C. Gonzi <sup>1</sup>, S. Macrini <sup>2</sup>, E. Cordova <sup>1</sup>, M. Bassanelli <sup>2</sup>, F. Festuccia <sup>1</sup>, P. Marchetti <sup>2</sup>, P. Menè <sup>1</sup>  
<sup>(1)</sup> Division of Nephrology, Sant'Andrea Hospital, University of Rome "Sapienza", <sup>(2)</sup> Division of Medical Oncology, Sant'Andrea Hospital, University of Rome "Sapienza"

- 14.** Acute coronary syndrome after Axitinib to Sorafenib shift in metastatic renal cell carcinoma clear cell type  
**A. Gaballo**<sup>1</sup>, **M. Gregorini**<sup>1</sup>, **C. Porta**<sup>2</sup>, **B. Marinoni**<sup>3</sup>, **A. Turco**<sup>3</sup>, **E. Pattonieri**<sup>4</sup>, **C. Libetta**<sup>4</sup>, **T. Rampino**<sup>1</sup>  
<sup>(1)</sup> 1SC Nefrologia, Dialisi e Trapianto, Fondazione IRCCS Policlinico San Matteo Pavia e Università degli Studi di Pavia, <sup>(2)</sup> 3Oncologia Medica, IRCCS Fondazione Policlinico San Matteo, Pavia, <sup>(3)</sup> 5 SC Cardiologia, Fondazione IRCCS Policlinico San Matteo Pavia, <sup>(4)</sup> 4 Dottorato in Medicina Sperimentale, Università degli Studi di Pavia
- 15.** Small cell lung carcinoma associated with Focal and Segmental Glomerulosclerosis. Careful work-up for renal biopsy may uncover a hidden neoplasia  
**M. Giliberti**<sup>1</sup>, **P. Gallo**<sup>1</sup>, **C. Villani**<sup>1</sup>, **C. Manno**<sup>1</sup>, **L. Gesualdo**<sup>1</sup>, **V. Montinaro**<sup>1</sup>  
<sup>(1)</sup> Division of Nephrology and Postdoctoral Specialty Program in Nephrology, Azienda Ospedaliero-Universitaria Consorziale Policlinico Bari, Italy, Università degli Studi "Aldo Moro", Bari, Italy
- 16.** Renal Immune Related Adverse Events Associated with anti-PD1 inhibitors: Experience at a Large Cancer Center  
**I. Glezerman**<sup>1</sup>, **E. Jaimes**<sup>1</sup>  
<sup>(1)</sup> Renal Service, Memorial Sloan Kettering Cancer Center, New York, NY
- 17.** Autologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients. A single Centre Experience  
**G. Joli**<sup>1</sup>, **G. Slaviero**<sup>2</sup>, **C. Lanzani**<sup>1</sup>, **P. Manunta**<sup>1</sup>, **C. Messina**<sup>2</sup>, **F. Pavesi**<sup>2</sup>, **M. Carrabba**<sup>2</sup>, **M. Bernardi**<sup>2</sup>, **F. Ciceri**<sup>1</sup>  
<sup>(1)</sup> University Vita Salute San Raffaele, Milan - IRCCS San Raffaele Scientific Institute, Milan, <sup>(2)</sup> IRCCS San Raffaele Scientific Institute, Milan
- 18.** Characteristic miRNA patterns involved in metastases in laryngeal cancer patients  
**H. Kawasaki**<sup>1</sup>, **M. Caraglia**<sup>1</sup>  
<sup>(1)</sup> University of Campania Luigi Vanvitelli19. Chronic kidney disease and anemia in patients with colorectal and breast cancer
- 19.** Chronic kidney disease and anemia in patients with colorectal and breast cancer  
**K. Kozłowska**<sup>1</sup>, **J. Malyszko**<sup>1</sup>, **L. Kozłowski**<sup>2</sup>  
<sup>(1)</sup> The Medical University of Białystok Clinical Hospital, 2nd Department of Nephrology, Białystok, POLAND, <sup>(2)</sup> Ministry of Interior and Administration hospital in Białystok, Department of Surgical Oncology, Białystok, POLAND.
- 20.** Acute renal failure secondary to multifocal tubulointerstitial and intraglomerular metastatic malignant melanoma  
**J.S. Lin**<sup>1</sup>, **O. Mamlouk**<sup>2</sup>, **W.F. Glass**<sup>3</sup>, **R.N. Amaria**<sup>4</sup>, **A. Lahoti**<sup>1</sup>, **B. Workeneh**<sup>1</sup>  
<sup>(1)</sup> Division of Internal Medicine, Section of Nephrology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA, <sup>(2)</sup> Department of Internal Medicine, Division of Renal Diseases and Hypertension, University of Texas Health Science Center McGovern Medical School, Houston, Texas, USA, <sup>(3)</sup> Department of Pathology and Laboratory Medicine, University of Texas Health Science Center McGovern Medical School, Houston, Texas, USA, <sup>(4)</sup> Department of Melanoma Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
- 21.** Genetic determinants in the development of hypertension in patients surviving long-after bone marrow transplant  
**L. Macrina**<sup>1</sup>, **E. Messaggio**<sup>1</sup>, **L. Citterio**<sup>1</sup>, **C. Lanzani**<sup>1</sup>, **P. Manunta**<sup>1</sup>, **C. Messina**<sup>2</sup>, **E. Guggiari**<sup>2</sup>, **F. Lorentino**<sup>2</sup>, **E. Xue**<sup>2</sup>, **F. Ciceri**<sup>1</sup>  
<sup>(1)</sup> University Vita Salute San Raffaele, Milan - IRCCS San Raffaele Scientific Institute, Milan, <sup>(2)</sup> IRCCS San Raffaele Scientific Institute, Milan
- 22.** Antiangiogenic drugs and kidney: easy or hard connection? A case description  
**M. Erolı**<sup>1</sup>, **R. Radoja**<sup>1</sup>, **A. Giordano**<sup>1</sup>, **L. Cencioni**<sup>1</sup>, **F. Di Costanzo**<sup>2</sup>, **B. Di Girolamo**<sup>2</sup>, **S. Venanzi**<sup>3</sup>  
<sup>(1)</sup> U.O Nefrologia e Dialisi - Ospedale Santa Maria della Stella - Orvieto (Terni), <sup>(2)</sup> U.O Oncologia- Ospedale Santa Maria della Stella - Orvieto (Terni), <sup>(3)</sup> U.O Nefrologia e Dialisi- Ospedale San Matteo degli Infermi - Spoleto (Perugia)
- 23.** AL amyloidosis: still the bitterest gammopathy presentation?  
**Valério, Patricia; Farinha, Ana**  
Nephrology Department - Centro Hospitalar de Setúbal. Portugal
- 24.** Management of nephrectomized cancer patients receiving or not active oncological treatment  
**M. Vischi**<sup>1</sup>, **M. Pedone**<sup>2</sup>, **L. Cosmai**<sup>1</sup>, **C. Porta**<sup>3</sup>, **M. Gallieni**<sup>4</sup>  
<sup>(1)</sup> Nephrology and Dialysis Unit, San Carlo Borromeo Hospital, ASST Santi Paolo e Carlo, Milan, Italy, <sup>(2)</sup> Specializing in Nephrology, University of Milan, Milan, <sup>(3)</sup> Medical Oncology, IRCCS San Matteo University Hospital Foundation, Pavia, Italy, <sup>(4)</sup> Nephrology and Dialysis Unit, San Carlo Borromeo Hospital, ASST Santi Paolo e Carlo, Milan, Italy, Department of Clinical and Biomedical Sciences "Luigi Sacco", University of Milan, Milan, Italy

# December 8<sup>th</sup>, 2017

**1.00 pm - 2.30 pm**

*Discussant:*

**Claudio Pisano, Domenico Russo,  
Floriana Morgillo, Erica Martinelli**

- 1. Trifluridine and tipiracil-induced leukocytoclastic vasculitis with late-onset Henoch-Schönlein purpura nephritis**  
**J.S. Lin <sup>1</sup>, A. Lahoti <sup>1</sup>**  
<sup>(1)</sup> Division of Internal Medicine, Section of Nephrology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
- 2. Tumor endothelial cells could provide tumor niche and promote metastasis through extracellular vesicles**  
**T. Lopatina <sup>1</sup>, S. Fallo <sup>1</sup>, C. Grange <sup>1</sup>, C. Roma <sup>1</sup>, E. Favaro <sup>1</sup>, G. Camussi <sup>1</sup>**  
<sup>(1)</sup> University of Turin
- 3. Humoral and genetic determinants in the development of kidney complications in patients with hematological malignancies after chemotherapy and/or allogeneic/autologous bone marrow transplant -**  
**L. Macrina <sup>1</sup>, E. Messaggio <sup>1</sup>, L. Citterio <sup>1</sup>, C. Lanzani <sup>1</sup>, P. Manunta <sup>1</sup>, C. Messina <sup>2</sup>, E. Guggiari <sup>2</sup>, F. Lorentino <sup>2</sup>, E. Xue <sup>2</sup>, F. Ciceri <sup>1</sup>**  
<sup>(1)</sup> University Vita Salute San Raffaele, Milan - IRCCS San Raffaele Scientific Institute, Milan,  
<sup>(2)</sup> IRCCS San Raffaele Scientific Institute, Milan
- 4. Malignancy prevalence in waitlisted potential kidney transplant recipients is very low relative to patients after kidney transplantation**  
**M. Malyszko <sup>1</sup>, J. Malyszko <sup>2</sup>**  
<sup>(1)</sup> 2nd Department of Nephrology, Medical University of Bialystok, <sup>(2)</sup> 1st Department of Nephrology, Medical University of Bialystok
- 5. Late lymphoproliferative disorders after kidney transplantation (TX): a severe complication that we must keep in mind.**  
**C. Manenti <sup>1</sup>, C. Salviani <sup>1</sup>, N. Bossini <sup>2</sup>, G. Setti <sup>2</sup>, F. Valerio <sup>2</sup>, S. Sandrini <sup>2</sup>, G. Cancarini <sup>1</sup>**  
<sup>(1)</sup> Department of Nephrology, ASST Spedali Civili di Brescia and University, Brescia, Italy,  
<sup>(2)</sup> Department of Nephrology, ASST Spedali Civili di Brescia, Brescia, Italy
- 6. Adverse renal effects of immune checkpoint inhibitors**  
**E. Cataldo <sup>1</sup>, G. D'ettore <sup>1</sup>, S. Matino <sup>1</sup>, U. Mercurio <sup>1</sup>, M. Taurisano <sup>1</sup>**  
<sup>(1)</sup> U.O.C Nefrologia Policlinico di Bari
- 7. Malignant melanoma and nephrotic syndrome**  
**A. Messias <sup>1</sup>, A. Azevedo <sup>1</sup>, J. Calado <sup>1</sup>, H. Viana <sup>1</sup>, F. Nolasco <sup>1</sup>**  
<sup>(1)</sup> Nephrology Department, Hospital Curry Cabral, Centro Hospitalar Lisboa Central, Lisboa, Portugal
- 8. Isolated bilateral kidney relapse of acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. A case report**  
**C. Messina <sup>1</sup>, R. Milani <sup>1</sup>, L. Vago <sup>1</sup>, F. Giglio <sup>1</sup>, A. Assanelli <sup>1</sup>, C. Corti <sup>1</sup>, C. Lanzani <sup>2</sup>, P. Manunta <sup>2</sup>, M. Venturini <sup>1</sup>, F. Ciceri <sup>2</sup>**  
<sup>(1)</sup> IRCCS San Raffaele Scientific Institute, Milan, <sup>(2)</sup> University Vita Salute San Raffaele, Milan - IRCCS San Raffaele Scientific Institute, Milan
- 9. Treatment of renal angiomyolipomas in tuberous sclerosis: current evidence of mTOR inhibitors**  
**N. Moreira Fonseca <sup>1</sup>, C. Silva <sup>1</sup>, F. Nolasco <sup>1</sup>**  
<sup>(1)</sup> Centro Hospitalar Lisboa Central
- 10. Proteinuria is a late onset adverse event in patients treated with cabozantinib**  
**D. Moriconi <sup>1</sup>, V. Cappagli <sup>2</sup>, D. Viola <sup>2</sup>, V. Bottici <sup>2</sup>, R. Elisei <sup>2</sup>, M.F. Egidi <sup>1</sup>**  
<sup>(1)</sup> University of Pisa, Unit of Nephrology, Dialysis, Transplantation, <sup>(2)</sup> University of Pisa, Unit of Endocrinology
- 11. Dialysis membranes interact with Circulating Tumor Cells: an in vivo and ex vivo study -**  
**A. Naticchia <sup>1</sup>, G. Canu <sup>2</sup>, C. Autilio <sup>2</sup>, E. Capoluongo <sup>2</sup>, G. Gambaro <sup>3</sup>**  
<sup>(1)</sup> Fondazione Policlinico Universitario A. Gemelli, Nephrology Unit, <sup>(2)</sup> Fondazione Policlinico Universitario A. Gemelli, Department of Clinical Molecular Diagnostics, <sup>(3)</sup> Fondazione Policlinico Universitario A. Gemelli, Nephrology Unit
- 12. Crizotinib, serum creatinine and acute renal failure: ménage à trois -**  
**M. Pedone <sup>1</sup>, M. Vischi <sup>2</sup>, L. Tagliabue <sup>3</sup>, M. Pagano <sup>4</sup>, L. Cosmai <sup>2</sup>, M. Gallieni <sup>5</sup>**  
<sup>(1)</sup> Specializing in Nephrology, University of Milan, Milan, <sup>(2)</sup> Nephrology and Dialysis Unit, San Carlo Borromeo Hospital, ASST Santi Paolo e Carlo, Milan, Italy, <sup>(3)</sup> Nuclear Medicine Unit, San Paolo Hospital, ASST Santi Paolo e Carlo, Milan, Italy, <sup>(4)</sup> Oncology, IRCCS ASMN, Reggio Emilia, Italy, <sup>(5)</sup> Nephrology and Dialysis Unit, San Carlo Borromeo Hospital, ASST Santi Paolo e Carlo, Milan, Italy, Department of Clinical and Biomedical Sciences "Luigi Sacco", University of Milan, Milan, Italy

- 13.** Interleukin-27 has a potential predictive role in the onset of post-transplant malignancies  
P. Pontrelli <sup>1</sup>, F. Rascio <sup>2</sup>, G. Stallone <sup>2</sup>, M. Accetturo <sup>3</sup>, G. Castellano <sup>3</sup>, B. Infante <sup>2</sup>, G. Zaza <sup>4</sup>, A. Lupo <sup>4</sup>, L. Gesualdo <sup>3</sup>, G. Grandaliano <sup>2</sup>  
<sup>(1)</sup> Nephrology Unit, Dept. of Emergency and Organ Transplantation, University of Bari "Aldo Moro", Italy, <sup>(2)</sup> Nephrology Unit, Dept. of Medical and Surgical Sciences, University of Foggia, Italy, <sup>(3)</sup> Nephrology Unit, Dept. of Emergency and Organ Transplantation, University of Bari "Aldo Moro", Italy, <sup>(4)</sup> Nephrology Unit, Dept. of Medicine, University of Verona, Italy
- 14.** A quite unique case of rapidly progressive glomerulonephritis following desametasone/ bortezomib/ thalidomide treatment for myeloma -  
U. Vertolli <sup>1</sup>, T. Berno <sup>2</sup>, F. Adami <sup>2</sup>, L. Qassim <sup>1</sup>, L.A. Calò <sup>1</sup>  
<sup>(1)</sup> Dept Medicine, Nephrology, University of Padova, <sup>(2)</sup> Dept Medicine, Hematology, University of Padova
- 15.** Nephrotoxicity of the chemotherapy in arcc. A case description  
R. Radoja <sup>1</sup>, M. Erolì <sup>1</sup>, A. Giordano <sup>1</sup>, L. Cencioni <sup>1</sup>, S. Venanzi <sup>2</sup>  
<sup>(1)</sup> OSPEDALE SANTA MARIA DELLA STELLA, ORVIETO, <sup>(2)</sup> OSPEDALE SAN MATTEO DEGLI INFERRMI, SPOLETO
- 16.** Myeloma in the young is not so rare! Case report  
P. Ria <sup>1</sup>, A. De Pascalis <sup>1</sup>, A. Armeni <sup>1</sup>, A. Zito <sup>1</sup>, G.A. Caloro <sup>1</sup>, M. Napoli <sup>1</sup>  
<sup>(1)</sup> Division of Nephrology, Department of Medicine, "V.Fazzi" Hospital, Lecce, Italy.
- 17.** Post-transplant lymphoproliferative disorders: a diagnostic dilemma  
A. Ronchi <sup>1</sup>, G. Conte <sup>2</sup>, A. Camocardi <sup>2</sup>, V. Coluccino <sup>3</sup>, R. Franco <sup>1</sup>  
<sup>(1)</sup> Division of Pathology, Department of Salute mentale e fisica e medicina preventiva, Università della Campania "L. Vanvitelli", Naples, Italy, <sup>(2)</sup> Division of Nephrology, Department of Scienze Mediche, Chirurgiche, Neurologiche, Metaboliche e dell'Invecchiamento, Università della Campania "L. Vanvitelli", Naples, Italy, <sup>(3)</sup> Department of Pathology, S. Maria del Popolo degli Incurabili Hospital ASL NA1, Naples, Italy
- 18.** Urinary Cystatin C as an early predictor of AKI induced by cisplatin and its analogues -  
A. Sabry <sup>1</sup>, M. Elkot <sup>1</sup>, A. Abdelwahab <sup>1</sup>  
<sup>(1)</sup> Nephrology and Dialysis unit - Mansoura university - Mansoura city
- 19.** In vitro Culture of Patient Derived Kidney Organoids  
K. Sutha <sup>1</sup>, Y. Ju <sup>2</sup>, J.T. Neal <sup>3</sup>, C. Kuo <sup>2</sup>  
<sup>(1)</sup> Division of Pediatric Nephrology, Lucile Packard Children's Hospital Stanford, Palo Alto, CA, USA, <sup>(2)</sup> Division of Hematology, Stanford University Medical Center, Palo Alto, CA, USA, <sup>(3)</sup> Broad Institute of MIT and Harvard, Cambridge, MA, USA
- 20.** Late onset EBV negative post-transplant lymphoproliferative disease in renal recipient  
M. Taurisano <sup>1</sup>, G. D'ettore <sup>1</sup>, S. Matino <sup>1</sup>, E. Cataldo <sup>1</sup>, U. Mercurio <sup>1</sup>  
<sup>(1)</sup> U.O.C. Nefrologia, Dialisi e Trapianto Università di Bari
- 21.** Adjunction of a MEK inhibitor to Vemurafenib in the treatment of metastatic melanoma results in a 60% reduction of acute kidney injury  
C. Teuma <sup>1</sup>, S. Pelletier <sup>1</sup>, M. Perier-Muzet <sup>2</sup>, M. Nouvier <sup>1</sup>, F. Dijoud <sup>3</sup>, S. Dalle <sup>2</sup>, D. Fouque <sup>1</sup>  
<sup>(1)</sup> Nephrology, Centre Hospitalier Lyon Sud, <sup>(2)</sup> Dermatology, Centre Hospitalier Lyon Sud, <sup>(3)</sup> Anatomopathology, Groupement Hospitalier Est
- 22.** The Association of Uromodulin Genotype with Renal Cancer Aggressiveness  
F. Trevisani <sup>1</sup>, A. Larcher <sup>1</sup>, A. Cinque <sup>1</sup>, U. Capitano <sup>1</sup>, F. Ripa <sup>1</sup>, A. Bettiga <sup>1</sup>, A. Briganti <sup>1</sup>, A. Salonia <sup>1</sup>, L. Rampoldi <sup>2</sup>, F. Montorsi <sup>1</sup>  
<sup>(1)</sup> URI - Urological Research Institute, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy, <sup>(2)</sup> Division of Genetics and Cell Biology, IRCCS San Raffaele Scientific Institute, Milan, Italy
- 23.** Membranous nephropathy: when not to forget cancer  
P. Valerio <sup>1</sup>, F. Ana <sup>1</sup>  
<sup>(1)</sup> Servizio Nefrologia, Centro Hospitalar de Setubal
- 24.** Acute kidney injury after radical nephrectomy as risk factor for CKD: retrospective analysis from an Italian Cancer Center  
M. Vischi <sup>1</sup>, L. Cosmai <sup>1</sup>, M. Pedone <sup>2</sup>, C. Porta <sup>3</sup>, M. Gallieni <sup>4</sup>  
<sup>(1)</sup> Nephrology and Dialysis Unit, San Carlo Borromeo Hospital, ASST Santi Paolo e Carlo, Milan, Italy, <sup>(2)</sup> Specializing in Nephrology, University of Milan, Milan, <sup>(3)</sup> Medical Oncology, IRCCS San Matteo University Hospital Foundation, Pavia, Italy, <sup>(4)</sup> Nephrology and Dialysis Unit, San Carlo Borromeo Hospital, ASST Santi Paolo e Carlo, Milan, Italy, Department of Clinical and Biomedical Sciences "Luigi Sacco", University of Milan, Milan, Italy
- 25.** Tracking single immune cell for 24h: Real-time intravital study with GPU acceleration -  
M. Vladymyrov <sup>1</sup>, A. Ariga <sup>1</sup>  
<sup>(1)</sup> University of Bern, LHEP, Bern



# General Information

## CONGRESS VENUE

**Aula Magna - Congress Centre**

Via Partenope, 36 - 80121 Naples (Italy)

## SECRETARIAT CORNER

The Secretariat will be open at the following times:

- Thursday, December 7<sup>th</sup>, 2017 from 7.00 a.m. to 6.30 p.m.
- Friday, December 8<sup>th</sup>, 2017 from 7.30 a.m. to 6.30 p.m.
- Saturday, December 9<sup>th</sup>, 2017 from 7.30 a.m. to 4.30 p.m.

## OFFICIAL LANGUAGE

The official language of the Congress will be English.  
Simultaneous translation service will not be provided.

## CONTINUING MEDICAL EDUCATION (CME)

Planning Congressi S.r.l. is a CME provider - identification code no. 38 - and has assigned to the event no. **6** credits for Physicians for the following disciplines: internal medicine, oncology, pediatrics, pharmacology, nephrology, primary care, genetics, ophthalmology, hematology, cardiology, urology, endocrinology, geriatrics, metabolic diseases. Credits will be assigned also to: Biologists, Midwives, Oculists, Chemists, Epidemiologists, Audiologists, medical genetic laboratory Technicians, Neonatologists, Therapists of the Neuro and Psychomotor Developmental. Please be aware that for the acquisition of credits is mandatory to have attended the 100% of the whole duration of the congress and selected at least the 75% of correct answers of the CME questionnaire.

## EUROPEAN CME CREDITS (ECME C'S)

The International Conference, code no. 00837 was granted 18 European CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME).

## REGISTRATION

The Conference is free to attend.



## **SPEAKERS' READY ROOM**

Invited speakers and oral abstract presenters are invited to deliver their presentation to the Speakers' Ready Room at least one hour before the session starts. For a morning presentation on Friday and Saturday, please report to the Speakers' Ready Room the day before up until 6.00.p.m.

The Speakers' Ready Room will be open during the following times:

- Thursday, December 7<sup>th</sup> 2017 from 7.00 a.m. to 6.30 p.m.
- Friday, December 8<sup>th</sup>, 2017 from 7.30 a.m. to 6.30 p.m.
- Saturday, December 9<sup>th</sup>, 2017 from 7.30 a.m. to 4.30 p.m.

## **LUNCHES AND COFFEE BREAKS**

Lunches and coffee breaks will be free of charge and served at the congress venue.

## **CERTIFICATES OF ATTENDANCE**

Certificates of attendance will be issued at the registration desk following full attendance of the congress.

## **POSTER SESSIONS**

Posters will be presented on different days during the Congress and are accessible at the same times.

The official poster sessions will take place as follows:

- Thursday, December 7<sup>th</sup> 2017 from 1.00 p.m. to 2.30 p.m.
- Friday, December 8<sup>th</sup>, 2017 from 1.15 p.m. to 2.45 p.m.

## **ORGANIZING SECRETARIAT**

WE DRIVE YOUR EDUCATION

## **PLANNING**

### **Planning Congressi S.r.l.**

Via Guelfa 9

40138 Bologna (Italy)


*Project Leader:* Claudia Magri

Email: [c.magri@planning.it](mailto:c.magri@planning.it)

Phone +39 051 300100 Ext. 157

Fax +39 051 309477

Mobile +39 346 3676568



# International Conference **OncoNephrology**

An Emerging Field In Medicine

Naples (Italy), December 7-9, 2017

Promoted by



FONDAZIONE  
INTERNAZIONALE  
MENARINI

## ORGANIZING SECRETARIAT

WE DRIVE YOUR EDUCATION

## PLANNING

Planning Congressi S.r.l.

Via Guelfa 9

40138 Bologna (Italy)

Phone +39 051 300100 Ext. 157

Fax +39 051 309477

Mobile +39 346 3676568

Email: [c.magri@planning.it](mailto:c.magri@planning.it)



Leading  
European  
Nephrology

*ERA-EDTA's endorsement is for the promotion of education in general,  
therefore the specific content of the event/course  
is the responsibility of the organizer*